Navigation Links
SynCo Bio Partners Expands the Class A Zone in its Aseptic Filling Facility
Date:8/4/2011

AMSTERDAM, The Netherlands, August 4, 2011 /PRNewswire/ --

SynCo Bio Partners B.V., one of the leading GMP contract manufacturers of biopharmaceuticals today announced that its aseptic filling facility is again fully operational and SynCo has produced and released the first drug product batches for its clients after the expansion of its Class A zone.  

The expansion of the Class A zone is an important milestone in SynCo's strategy in supporting its clients with new product launches in the US and the rest of the world.  SynCo's aseptic filling facility is able to fill and lyophilize a wide range of biopharmaceuticals which include proteins, monoclonal antibodies, polysaccharides, nucleic acids, aluminium containing vaccines, RNA and live biotherapeutics for clinical and market supply.

Announcing this upgrade, Pierre Warffemius, CEO of SynCo Bio Partners said:

"The expansion of the Class A zone is an excellent addition to SynCo Bio Partners' already state-of-the-art contract manufacturing facility in Amsterdam. SynCo is one of the few biopharmaceutical CMOs in the world with a recognized track record in both clinical and commercial manufacturing of both bulk drug substance and drug product and continuously invests in its facilities to achieve its goal: Trust us to make it right."

About SynCo Bio Partners B.V.

SynCo Bio Partners B.V. is a biopharmaceutical GMP Contract Manufacturing Organization located in Amsterdam, The Netherlands, licensed for clinical and commercial GMP manufacturing of Bulk Drug Substances and Drug Products.  As a truly global player, SynCo offers a fully integrated range of biopharmaceutical development and manufacturing services supporting small biotech to large pharmaceutical organizations worldwide from the earliest stages in process development, through pre-clinical and clinical trials, biologic license approval and market supply. For more information, please visit http://www.syncobiopartners.com


'/>"/>
SOURCE SynCo Bio Partners B.V.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Inovio Pharmaceuticals Enters Phase II Clinical Trial with SynCon™ DNA Vaccine for Cervical Dysplasia Caused by HPV
2. SynCo Bio Partners and Versartis Expand Collaboration as Lead Product Enters into Clinical Trials
3. SynCo Bio Partners Signs New Manufacturing Agreements to Supply the US Market; Securing its Position as a Market Leader in Microbial Biopharmaceutical Contract Production
4. SynCo Bio Partners Enters the Japanese Market as it Signs its First Agreement With a Japanese Pharmaceutical Company
5. SynCo Bio Partners to Manufacture Versartis Novel Drug for Type 2 Diabetes
6. SynCo Bio Partners Increases its Capacities by Expanding its Quality Team
7. SynCo Bio Partners Wins Best Contract Manufacturing Organization 2009 ViE Award
8. INC Research and Debiopharm Group(TM) Announce Strategic Partnership
9. Hitachi partnership brings new tools and electron microscope reference center to Edmonton
10. Emerson Ecologics Expands Partnership With Metagenics, Announces National Distribution Agreement
11. HCCS Partners with American Association of Critical Care Nurses (AACN) to Offer Nurse Training
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2017)... ... April 27, 2017 , ... During the course of ... testing for 1,25-Dihydroxyvitamin D can enhance clinical practice. Participants will learn the medical ... D. , Dr. Gregory Plotnikoff, senior consultant with Minnesota Personalized Medicine, will be ...
(Date:4/27/2017)... April 27, 2017  Pendant Biosciences, Inc. (formerly Nanoferix, ... modification and drug delivery technologies, today announced that it ... @ Toronto . ... Pendant Biosciences, noted, "We are excited to become part ... community, and are honored to be the first ...
(Date:4/26/2017)... ... April 25, 2017 , ... LABS, Inc. (LABS) announced in December 2016 ... extensive test menu: Nucleic Acid Testing (NAT) for ZIKV; and Enzyme Immunoassays (EIAs) specific ... offer NAT screening for blood donors under an Investigational New Drug (IND) study protocol. ...
(Date:4/25/2017)... ... April 25, 2017 , ... As part of the ... explore the laboratory testing for DIC in order to illuminate this clinical problem for ... occur in hospitalized patients resulting in a high degree of morbidity and mortality. DIC ...
Breaking Biology Technology:
(Date:3/30/2017)... , March 30, 2017 Trends, opportunities and ... and behavioral), by technology (fingerprint, AFIS, iris recognition, facial ... and others), by end use industry (government and law ... financial and banking, and others), and by region ( ... , Asia Pacific , and the ...
(Date:3/28/2017)... 2017 The report "Video Surveillance ... Servers, Storage Devices), Software (Video Analytics, VMS), and Service ... Forecast to 2022", published by MarketsandMarkets, the market was ... projected to reach USD 75.64 Billion by 2022, at ... base year considered for the study is 2016 and ...
(Date:3/24/2017)... The Controller General of Immigration from Maldives Mr. Mohamed Anwar ... the prestigious international IAIR Award for the most innovative high security ePassport ... ... Maldives Immigration Controller General, Mr. ... on the right) have received the IAIR award for the "Most innovative ...
Breaking Biology News(10 mins):